Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433301 | 0.82 | SCN9A (0.39) | SCN9A | |
| SCHEMBL16094136 | 0.82 | THRA (0.38) | THRATHRBCGASPARP15PARP10 | |
| SCHEMBL16119903 | 0.81 | SCN9A (0.38) | SCN9A | |
| SCHEMBL19225529 | 0.75 | RIPK1 (0.37) | THRATHRBCGASPARP15PARP10 | |
| SCHEMBL5777914 | 0.74 | LMNA (0.50) | THRATHRBMCHR1 | |
| SCHEMBL15777787 | 0.74 | RIPK1 (0.36) | PARP15PARP10SCN9A | |
| SCHEMBL8224255 | 0.73 | LMNA (0.51) | THRATHRBMCHR1 | |
| SCHEMBL17433292 | 0.71 | HPGD (0.34) | SCN9A | |
| SCHEMBL21949867 | 0.70 | PKM (0.49) | THRATHRBPARP10MCHR1SLC6A4 | |
| SCHEMBL16102737 | 0.70 | KDM4C (0.46) | THRATHRBMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | THRA 406/4885THRB 813/4885CGAS 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.